Children's oncology Group's 2013 blueprint for research: Central nervous system tumors

Amar Gajjar, Roger J. Packer, N. K. Foreman, Kenneth Cohen, Daphne Haas-Kogan, Thomas E. Merchant

Research output: Contribution to journalReview article

Abstract

In the US, approximately 2,500 children are diagnosed annually with brain tumors. Their survival ranges from >90% to <10%. For children with medulloblastoma, the most common malignant brain tumor, 5-year survival ranges from >80% (standard-risk) to 60% (high-risk). For those with high-grade gliomas (HGGs) including diffuse intrinsic pontine gliomas, 5-year survival remains <10%. Sixty-five percent patients with ependymoma are cured after surgery and radiation therapy depending on the degree of resection and histopathology of the tumor. Phase II trials for brain tumors will investigate agents that act on cMET, PDGFRA, or EZH2 in HGG, DIPG, or medulloblastoma, respectively. Phase III trials will explore risk-based therapy stratification guided by molecular and clinical traits of children with medulloblastoma or ependymoma.

Original languageEnglish (US)
Pages (from-to)1022-1026
Number of pages5
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 2013

Keywords

  • Ependymoma
  • High-grade glioma and diffuse intrinsic pontine glioma
  • Medulloblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Children's oncology Group's 2013 blueprint for research: Central nervous system tumors'. Together they form a unique fingerprint.

  • Cite this

    Gajjar, A., Packer, R. J., Foreman, N. K., Cohen, K., Haas-Kogan, D., & Merchant, T. E. (2013). Children's oncology Group's 2013 blueprint for research: Central nervous system tumors. Pediatric Blood and Cancer, 60(6), 1022-1026. https://doi.org/10.1002/pbc.24427